134 related articles for article (PubMed ID: 38100982)
21. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
22. Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses.
Liu T; Zhang Y; Cao Y; Jiang S; Sun R; Yin J; Gao Z; Ren G; Wang Z; Yu Q; Sui G; Sun X; Sun W; Xiao W; Li D
Gene Ther; 2021 Dec; 28(12):697-717. PubMed ID: 32409746
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells.
Sun Y; Tang L; Kan X; Tan L; Song C; Qiu X; Liao Y; Nair V; Ding C; Liu X; Sun Y
J Virol; 2024 Mar; 98(3):e0189723. PubMed ID: 38411946
[TBL] [Abstract][Full Text] [Related]
24. Autophagy is involved in recombinant Newcastle disease virus (rL-RVG)-induced cell death of stomach adenocarcinoma cells in vitro.
Bu XF; Wang MB; Zhang ZJ; Zhao YH; Li M; Yan YL
Int J Oncol; 2015 Aug; 47(2):679-89. PubMed ID: 26058483
[TBL] [Abstract][Full Text] [Related]
25. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines.
Santos MR; Xavier PLP; Pires PRL; Rochetti AL; Rosim DF; Scagion GP; de Campos Zuccari DAP; Munir M; Ferreira HL; Fukumasu H
Vet Comp Oncol; 2021 Sep; 19(3):593-601. PubMed ID: 33871162
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
Virol J; 2014 May; 11():84. PubMed ID: 24885546
[TBL] [Abstract][Full Text] [Related]
28. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection.
Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG
Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773
[TBL] [Abstract][Full Text] [Related]
29. Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.
Ahmad U; Abdullah S; Chau M; Chia SL; Yusoff K; Chan SC; Ong TA; Razack AH; Veerakumarasivam A
Sci Rep; 2023 May; 13(1):7323. PubMed ID: 37147328
[TBL] [Abstract][Full Text] [Related]
30. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
31. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
Zamarin D; Palese P
Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
[TBL] [Abstract][Full Text] [Related]
33. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Huang Z; Liu M; Huang Y
Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
36. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research.
Faranoush P; Jahandideh A; Nekouian R; Mortazavi P
Vet Med Sci; 2023 May; 9(3):1426-1437. PubMed ID: 36920334
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
[TBL] [Abstract][Full Text] [Related]
39. Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes.
Chan LC; Kalyanasundram J; Leong SW; Masarudin MJ; Veerakumarasivam A; Yusoff K; Chan SC; Chia SL
BMC Cancer; 2021 May; 21(1):625. PubMed ID: 34044804
[TBL] [Abstract][Full Text] [Related]
40. Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53.
Abd-Aziz N; Stanbridge EJ; Shafee N
J Gen Virol; 2016 Dec; 97(12):3174-3182. PubMed ID: 27902314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
